校正永恒时间偏倚后高度致敏患者与HLA脱敏肾移植受者的生存分析
该研究在法国单中心纳入326例高度致敏(PRA≥80%)等待肾移植患者,采用时间依赖协变量Cox模型校正永恒时间偏倚,比较脱敏移植、未脱敏移植与继续等待患者的全因死亡率。结果显示校正后三组死亡率无显著差异(HR=0.48,P=0.22),脱敏与未脱敏移植患者移植物存活及1年eGFR相似。
要点
- 校正永恒时间偏倚后,脱敏移植与未脱敏移植及等待患者死亡率无显著差异。
- 脱敏与未脱敏移植患者死亡删失移植物存活相似(HR=0.92,P=0.88)。
- 脱敏移植患者术后1年eGFR与未脱敏患者相似(53.3 vs 53.6 ml/min/1.73m2,P=0.95)。
核心结论
- HLA脱敏对高度致敏患者有效,可获得肾移植机会且不增加患者或移植物存活风险。
研究设计与样本
- 采用时间依赖协变量Cox生存模型校正永恒时间偏倚,并以landmark分析作为敏感性分析。
主要发现
- 随访期间147例(45%)仍在等待名单,179例接受肾移植。
- 校正永恒时间偏倚后,脱敏移植、未脱敏移植与等待患者全因死亡率无差异(HR=0.48,P=0.22)。
- 脱敏与未脱敏移植患者死亡删失移植物存活相似(校正供者年龄>65岁、供者状态及等待时间后HR=0.92,P=0.88)。
- 移植后1年平均eGFR在脱敏组为53.3±21 ml/min/1.73m2,未脱敏组为53.6±21 ml/min/1.73m2(P=0.95)。
临床怎么用
- 对高度致敏(PRA≥80%)肾移植等待患者,HLA脱敏可作为一种有效策略以增加移植机会。
- 评估脱敏移植结局时需注意校正永恒时间偏倚,以避免高估或低估疗效。
局限性
- 单中心回顾性研究,样本量有限(脱敏移植仅30例),结果需多中心验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the setting of kidney transplantation (KT), we assessed the efficacy of desensitization and compared the survival of desensitized patients (HLA-incompatible KT) with similarly sensitized patients receiving HLA-compatible KT or sensitized patients still on a waiting list after adjusting for the usually unaccounted immortal time bias. METHODS: All patients in a French KT center on the waiting list between August 1994 and December 2019 with a high level of sensitization (panel-reactive antibodies [PRAs] ≥80%) were included. The primary outcome was all-cause mortality. A time-varying covariate Cox survival model was used to account for the immortal time bias. A landmark analysis was used as a sensitivity analysis. RESULTS: During the study period, 326 patients with high PRAs were followed, among which 147 (45%) remained on the waiting list at the time of last follow-up and 179 benefited from a KT. Thirty-six patients were desensitized, of which 30 received a kidney transplant, including eight deceased kidney donors. There were no differences in mortality rates between desensitized KT patients, nondesensitized KT patients, and waitlisted patients after adjusting for immortal time bias (hazard ratio [HR] = 0.48, P = 0.22). Death-censored graft survival was similar between desensitized and nondesensitized KT patients (HR = 0.92, P = 0.88 adjusting for donor age >65 years, donor status, and time on the waiting list). Mean estimated glomerular filtration rate at 1 year post-KT was similar for desensitized KT patients (53.3 ± 21 vs. 53.6 ± 21 ml/min per 1.73 m2 for nondesensitized patients; P = 0.95). CONCLUSIONS: HLA-desensitization was effective for highly sensitized patients and gave access to KT without detrimental effects on patient or graft survival rates.
引用
- Noble J, Metzger A, Daligault M, et al. Immortal Time-Bias-Corrected Survival of Highly Sensitized Patients and HLA-desensitized Kidney Transplant Recipients. Kidney Int Rep. 2021. PMID: 34622102. doi:10.1016/j.ekir.2021.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。